Travis Steed
Stock Analyst at B of A Securities
(2.94)
# 967
Out of 4,479 analysts
57
Total ratings
36.96%
Success rate
1.57%
Average return
Main Sectors:
23 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SOLV Solventum | Maintains: Neutral | $70 → $60 | $51.45 | +16.62% | 2 | Jun 25, 2024 | |
| BDX Becton, Dickinson and Company | Maintains: Overweight | $305 → $312 | $229.27 | +36.08% | 6 | May 6, 2024 | |
| EW Edwards Lifesciences | Upgrades: Buy | n/a | $90.25 | - | 2 | Mar 7, 2024 | |
| BAX Baxter International | Maintains: Neutral | $42 → $45 | $33.06 | +36.12% | 5 | Mar 5, 2024 | |
| OM Outset Medical | Downgrades: Underperform | $32 → $3 | $3.69 | -18.70% | 1 | Oct 13, 2023 | |
| SYK Stryker | Upgrades: Buy | $315 | $336.50 | -6.39% | 4 | Sep 5, 2023 | |
| PODD Insulet | Maintains: Buy | $365 → $295 | $196.16 | +50.39% | 3 | Aug 24, 2023 | |
| AXGN AxoGen | Reiterates: Overweight | $16 | $7.71 | +107.52% | 4 | Aug 22, 2023 | |
| SILK Silk Road Medical | Downgrades: Underperform | $51 → $28 | $26.95 | +3.90% | 1 | Jul 12, 2023 | |
| TNDM Tandem Diabetes Care | Downgrades: Underperform | $45 → $33 | $39.45 | -16.35% | 2 | May 5, 2023 | |
| ZBH Zimmer Biomet Holdings | Upgrades: Neutral | $120 → $160 | $105.96 | +51.00% | 5 | May 3, 2023 | |
| ISRG Intuitive Surgical | Maintains: Buy | $300 → $315 | $436.24 | -27.79% | 2 | Apr 19, 2023 | |
| LUNG Pulmonx | Downgrades: Underperform | $8 | $6.24 | +28.21% | 1 | Jan 3, 2023 | |
| EMBC Embecta | Initiates: Underperform | $25 | $12.15 | +105.76% | 1 | Jun 21, 2022 | |
| ABT Abbott Laboratories | Maintains: Buy | $140 | $103.20 | +35.66% | 4 | May 31, 2022 | |
| INMD InMode | Maintains: Overweight | n/a | $17.87 | - | 3 | Oct 13, 2021 | |
| AXNX Axonics | Initiates: Overweight | n/a | $67.30 | - | 1 | Jul 12, 2021 | |
| DXCM DexCom | Initiates: Overweight | n/a | $112.17 | - | 4 | May 25, 2021 | |
| MDT Medtronic | Initiates: Equal-Weight | n/a | $77.12 | - | 1 | May 25, 2021 | |
| BSX Boston Scientific | Initiates: Overweight | n/a | $76.41 | - | 1 | May 25, 2021 | |
| CNMD CONMED | Initiates: Overweight | n/a | $66.99 | - | 1 | May 25, 2021 | |
| IART Integra LifeSciences Holdings | Maintains: Neutral | n/a | $28.97 | - | 2 | Nov 1, 2018 | |
| LNTH Lantheus Holdings | Initiates: Overweight | n/a | $80.00 | - | 1 | Jul 17, 2017 |
Solventum
Jun 25, 2024
Maintains: Neutral
Price Target: $70 → $60
Current: $51.45
Upside: +16.62%
Becton, Dickinson and Company
May 6, 2024
Maintains: Overweight
Price Target: $305 → $312
Current: $229.27
Upside: +36.08%
Edwards Lifesciences
Mar 7, 2024
Upgrades: Buy
Price Target: n/a
Current: $90.25
Upside: -
Baxter International
Mar 5, 2024
Maintains: Neutral
Price Target: $42 → $45
Current: $33.06
Upside: +36.12%
Outset Medical
Oct 13, 2023
Downgrades: Underperform
Price Target: $32 → $3
Current: $3.69
Upside: -18.70%
Stryker
Sep 5, 2023
Upgrades: Buy
Price Target: $315
Current: $336.50
Upside: -6.39%
Insulet
Aug 24, 2023
Maintains: Buy
Price Target: $365 → $295
Current: $196.16
Upside: +50.39%
AxoGen
Aug 22, 2023
Reiterates: Overweight
Price Target: $16
Current: $7.71
Upside: +107.52%
Silk Road Medical
Jul 12, 2023
Downgrades: Underperform
Price Target: $51 → $28
Current: $26.95
Upside: +3.90%
Tandem Diabetes Care
May 5, 2023
Downgrades: Underperform
Price Target: $45 → $33
Current: $39.45
Upside: -16.35%
Zimmer Biomet Holdings
May 3, 2023
Upgrades: Neutral
Price Target: $120 → $160
Current: $105.96
Upside: +51.00%
Intuitive Surgical
Apr 19, 2023
Maintains: Buy
Price Target: $300 → $315
Current: $436.24
Upside: -27.79%
Pulmonx
Jan 3, 2023
Downgrades: Underperform
Price Target: $8
Current: $6.24
Upside: +28.21%
Embecta
Jun 21, 2022
Initiates: Underperform
Price Target: $25
Current: $12.15
Upside: +105.76%
Abbott Laboratories
May 31, 2022
Maintains: Buy
Price Target: $140
Current: $103.20
Upside: +35.66%
InMode
Oct 13, 2021
Maintains: Overweight
Price Target: n/a
Current: $17.87
Upside: -
Axonics
Jul 12, 2021
Initiates: Overweight
Price Target: n/a
Current: $67.30
Upside: -
DexCom
May 25, 2021
Initiates: Overweight
Price Target: n/a
Current: $112.17
Upside: -
Medtronic
May 25, 2021
Initiates: Equal-Weight
Price Target: n/a
Current: $77.12
Upside: -
Boston Scientific
May 25, 2021
Initiates: Overweight
Price Target: n/a
Current: $76.41
Upside: -
CONMED
May 25, 2021
Initiates: Overweight
Price Target: n/a
Current: $66.99
Upside: -
Integra LifeSciences Holdings
Nov 1, 2018
Maintains: Neutral
Price Target: n/a
Current: $28.97
Upside: -
Lantheus Holdings
Jul 17, 2017
Initiates: Overweight
Price Target: n/a
Current: $80.00
Upside: -